Intercept Pharmaceuticals Financial Statements (ICPT)
|
|
|
|
Report date
|
|
|
01.03.2019 |
25.02.2020 |
25.02.2021 |
02.03.2022 |
02.03.2023 |
|
06.11.2023 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
179.8 |
252.0 |
312.7 |
363.5 |
285.7 |
|
317.7 |
|
Operating Income, bln rub |
|
|
-285.5 |
-312.4 |
-216.6 |
-55.8 |
-68.2 |
|
-62.3 |
|
EBITDA, bln rub |
? |
|
-278.7 |
-303.5 |
-212.2 |
-53.6 |
-61.7 |
|
-41.7 |
|
Net profit, bln rub |
? |
|
-309.2 |
-391.1 |
-324.2 |
-145.0 |
115.2 |
|
-58.6 |
|
|
OCF, bln rub |
? |
|
-240.7 |
-236.6 |
-170.0 |
-41.6 |
-26.8 |
|
-63.0 |
|
CAPEX, bln rub |
? |
|
0.167 |
1.14 |
3.89 |
0.397 |
0.568 |
|
0.408 |
|
FCF, bln rub |
? |
|
-240.9 |
-237.7 |
-173.9 |
-42.0 |
-27.3 |
|
-62.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
462.8 |
560.2 |
524.0 |
416.1 |
352.9 |
|
373.1 |
|
Cost of production, bln rub |
|
|
2.52 |
4.21 |
5.32 |
3.10 |
0.984 |
|
0.633 |
|
R&D, bln rub |
|
|
207.3 |
242.8 |
191.5 |
185.3 |
176.6 |
|
161.2 |
|
Interest expenses, bln rub |
|
|
30.5 |
41.1 |
48.1 |
54.4 |
21.4 |
|
9.98 |
|
|
Assets, bln rub |
|
|
509.2 |
754.9 |
580.5 |
527.0 |
553.7 |
|
393.2 |
|
Net Assets, bln rub |
? |
|
19.1 |
51.6 |
-166.9 |
-184.0 |
93.1 |
|
71.8 |
|
Debt, bln rub |
|
|
371.3 |
538.5 |
575.5 |
547.2 |
332.7 |
|
223.9 |
|
Cash, bln rub |
|
|
436.2 |
657.3 |
477.2 |
429.4 |
490.9 |
|
322.7 |
|
Net debt, bln rub |
|
|
-64.9 |
-118.8 |
98.3 |
117.8 |
-158.2 |
|
-98.9 |
|
|
Ordinary share price, rub |
|
|
100.8 |
123.9 |
24.7 |
16.3 |
12.4 |
|
19.0 |
|
Number of ordinary shares, mln |
|
|
28.5 |
31.7 |
33.0 |
31.9 |
33.8 |
|
41.8 |
|
|
Market cap, bln rub |
|
|
2 869 |
3 923 |
814 |
519 |
418 |
|
793 |
|
EV, bln rub |
? |
|
2 804 |
3 804 |
913 |
637 |
260 |
|
694 |
|
Book value, bln rub |
|
|
19 |
52 |
-167 |
-184 |
93 |
|
72 |
|
|
EPS, rub |
? |
|
-10.9 |
-12.4 |
-9.83 |
-4.55 |
3.41 |
|
-1.40 |
|
FCF/share, rub |
|
|
-8.46 |
-7.51 |
-5.28 |
-1.32 |
-0.81 |
|
-1.50 |
|
BV/share, rub |
|
|
0.67 |
1.63 |
-5.06 |
-5.77 |
2.75 |
|
1.72 |
|
|
EBITDA margin, % |
? |
|
-155.0% |
-120.5% |
-67.9% |
-14.7% |
-21.6% |
|
-13.1% |
|
Net margin, % |
? |
|
-172.0% |
-155.2% |
-103.7% |
-39.9% |
40.3% |
|
-18.4% |
|
FCF yield, % |
? |
|
-8.40% |
-6.06% |
-21.4% |
-8.10% |
-6.54% |
|
-7.92% |
|
ROE, % |
? |
|
-1 617% |
-758.5% |
194.3% |
78.8% |
123.7% |
|
-81.6% |
|
ROA, % |
? |
|
-60.7% |
-51.8% |
-55.9% |
-27.5% |
20.8% |
|
-14.9% |
|
|
P/E |
? |
|
-9.28 |
-10.0 |
-2.51 |
-3.58 |
3.63 |
|
-13.5 |
|
P/FCF |
|
|
-11.9 |
-16.5 |
-4.68 |
-12.3 |
-15.3 |
|
-12.6 |
|
P/S |
? |
|
16.0 |
15.6 |
2.60 |
1.43 |
1.46 |
|
2.50 |
|
P/BV |
? |
|
150.0 |
76.1 |
-4.88 |
-2.82 |
4.49 |
|
11.0 |
|
EV/EBITDA |
? |
|
-10.1 |
-12.5 |
-4.30 |
-11.9 |
-4.22 |
|
-16.7 |
|
Debt/EBITDA |
|
|
0.23 |
0.39 |
-0.46 |
-2.20 |
2.56 |
|
2.37 |
|
|
R&D/CAPEX, % |
|
|
124 132% |
21 373% |
4 921% |
46 668% |
31 098% |
|
39 513% |
|
|
CAPEX/Revenue, % |
|
|
0.09% |
0.45% |
1.24% |
0.11% |
0.20% |
|
0.13% |
|
| Intercept Pharmaceuticals shareholders |
